Mumbai, August 07, 2023: Lupin Digital Health (LDH), India’s leading Cardiac Digital Therapeutics company, today announced the launch of its newest offering, LyfeTM Digital Heart Failure Clinic in India. This groundbreaking e-clinic aims to help cardiologists and caregivers manage heart failure patients effectively from the comfort of their homes.

Heart failure affects over 10 million Indians today and is a progressive condition leading to repeated hospitalizations and is the leading cause of cardiac deaths. The LyfeTM Digital Heart Failure (HF) Clinic has been developed to address the growing burden on healthcare infrastructure due to increasing heart failure instances in India. It combines in-clinic consultation with at-home patient monitoring and care. A team of experts, including paramedics, nurses, cardiotherapists, health coaches and care managers, work together with the treating cardiologist to deliver improved patient health outcomes. The system is equipped with advanced technology, providing doctors with real-time updates and patients with personalized care pathways, emergency services and educational resources.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin Limited, said, “The launch of LyfeTM Digital HF clinic is a significant milestone in transforming cardiac care in India. We would like to partner with every cardiologist in India, augmenting them with a multidisciplinary team of experts to help them better manage their heart failure patients. Our solution combines AI-guided software and FDA/CE-approved devices to provide clinically actionable alerts and insights.”

“We are thrilled to introduce the LyfeTM Digital HF Clinic solution in India, a pioneering solution that brings cardiac care right to the homes of patients. Our aim is to support cardiologists and caregivers in effectively managing heart failure, ensuring improved health outcomes for patients. The initial results of this new initiative have been encouraging, with 88% compliance, improved biovitals, and reduced re-hospitalization. We are committed to making this innovative solution accessible to as many patients as possible through collaborations with cardiologists and hospitals”, said Sidharth Srinivasan, CEO, Lupin Digital Health.

Lupin Digital Health has recently partnered with the American College of Cardiology (ACC), further solidifying its commitment to drive innovation in cardiac care. This collaboration allows LDH to leverage ACC’s patient education resources, guidance on care pathways, and clinical inputs, empowering healthcare professionals and caregivers to deliver optimal patient care.

About Lupin Digital Health
Lupin Digital Health, a fully owned subsidiary of Lupin Limited, a leading global pharmaceutical company, is dedicated to developing cutting-edge digital health solutions that address unmet patient needs. Our flagship product, LyfeTM, is a revolutionary digital therapeutics solution that harnesses the power of artificial intelligence (AI) and machine learning (ML) to deliver personalized and immersive patient experiences. LyfeTM aims to tackle the critical challenge of effectively managing chronic diseases, thereby reducing the risks and expenses associated with hospitalization. By offering timely guidance on various health parameters, LyfeTM empowers individuals to take charge of their well-being. With its seamless integration of health monitoring devices, widespread technological accessibility, and the expertise of renowned cardiologists, LyfeTM provides a comprehensive cardiac care solution that enables individuals to regain control over their health and reshape the future of patient care.

Please visit  https://lyfe.in/ for more information.
Follow us on LinkedIn: https://www.linkedin.com/company/lupin-digital-health/

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on:
Twitter: https://twitter.com/LupinGlobal
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/

For further information or queries, please contact –

Priyanka Chavda
Manager – Corporate Communications
Email: priyankachavda@lupin.com